XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $216K invested in XTL Biopharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
10% less capital invested
Capital invested by funds: $240K → $216K (-$24.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$111 |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$92 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$555 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $179K | – | – | – |
|
|
2
Morgan Stanley
New York
| $36.4K | -$555 | -150 | -1% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $269 | +$92 | +25 | +50% |
|
|
4
UBS Group
Zurich,
Switzerland
| $108 | +$111 | +30 | New |
|
XTLB Hedge Fund Activity: Q3 2023 in Review
4 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2023, worth a combined $216K — down 10% from $240K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $111. The largest seller was Morgan Stanley, cutting an estimated $555.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2023, up from 3 in Q2 2023.
- Funds reported $216K of XTL Biopharmaceuticals stock for Q3 2023, down 10% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2023 was UBS Group, an estimated $111 added.
- The largest XTL Biopharmaceuticals seller in Q3 2023 was Morgan Stanley, an estimated $555 sold.
Based on aggregated 13F filings for Q3 2023.